Getein Biotech (603387) Fundamentals 2026 — P/E 18.8x, Revenue Analysis | SniperIQ
Getein Biotech (603387) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥4.4B, trading at ¥8.70 on the SHH. This SniperIQ fundamentals page covers Getein Biotech's valuation (P/E 18.8x, P/B 1.6x), profitability (net margin 21.6%), revenue (¥1.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Getein Biotech's market cap?
Getein Biotech (603387) has a market capitalization of approximately ¥4.4B, trading at ¥8.70 on the SHH. Market cap moves with the live share price.
What is Getein Biotech's P/E ratio?
Getein Biotech's trailing twelve-month P/E ratio is 18.8x, with a price-to-book (P/B) of 1.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Getein Biotech?
Getein Biotech runs a net profit margin of 21.6%, a gross margin of 66.7%, and an operating margin of 21.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Getein Biotech generate?
Getein Biotech reported revenue of ¥1.0B for fiscal year 2025, with net income of ¥221M and earnings per share (EPS) of 0.44. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Getein Biotech pay a dividend?
Getein Biotech offers a trailing dividend yield of about 2.8%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Getein Biotech financially healthy?
Getein Biotech carries a debt-to-equity ratio of 0.14x and a current ratio of 3.21x, with a market beta of 0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Getein Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Getein Biotech (603387) the key facts are: market cap ¥4.4B, P/E 18.8x, revenue ¥1.0B, 52-week range 7.37-11.42. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Getein Biotech's full fundamentals live
Get Getein Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.